Viking Therapeutics, Inc.
VKTX
$33.80
-$0.64-1.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.79% | -0.73% | -26.04% | -37.49% | 40.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 77.81% | 195.89% | 256.28% | 169.62% | 118.99% |
| Operating Income | -77.81% | -195.89% | -256.28% | -169.62% | -118.99% |
| Income Before Tax | -95.27% | -246.98% | -345.16% | -264.02% | -194.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -95.27% | -246.98% | -345.16% | -264.02% | -194.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -95.27% | -246.98% | -345.16% | -264.02% | -194.66% |
| EBIT | -77.81% | -195.89% | -256.28% | -169.62% | -118.99% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -88.32% | -236.44% | -334.74% | -259.40% | -190.03% |
| Normalized Basic EPS | -88.40% | -236.42% | -334.91% | -257.79% | -190.00% |
| EPS Diluted | -88.32% | -236.44% | -334.74% | -259.40% | -190.03% |
| Normalized Diluted EPS | -88.40% | -236.42% | -334.91% | -257.79% | -190.00% |
| Average Basic Shares Outstanding | 3.68% | 3.12% | 2.39% | 1.27% | 1.58% |
| Average Diluted Shares Outstanding | 3.68% | 3.12% | 2.39% | 1.27% | 1.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |